ライフサイエンスコーパス: lung transplantation

1 y was most outspoken in the first year after lung transplantation.

2 jor limiting factor of long-term survival in lung transplantation.

3 is (IPA) is a significant complication after lung transplantation.

4 transplantation but has not been examined in lung transplantation.

5 ppropriate management and early referral for lung transplantation.

6 primary graft failure or survival following lung transplantation.

7 sence of these organisms should not preclude lung transplantation.

8 siology of AR and for biomarker discovery in lung transplantation.

9 von Willebrand deficiency corrected through lung transplantation.

10 ng used as a reason to exclude patients from lung transplantation.

11 ous entity limiting long-term survival after lung transplantation.

12 patients (93 of 256) died, and one underwent lung transplantation.

13 al in a preclinical model of orthotopic left lung transplantation.

14 dence of acute rejection and infection after lung transplantation.

15 ing hazard associated with single- vs double-lung transplantation.

16 en referred to our center for evaluation for lung transplantation.

17 A total of 93 CF patients underwent lung transplantation.

18 promising approach to prevent IRI following lung transplantation.

19 s investigated in an orthotopic rat model of lung transplantation.

20 diagnosis of antibody-mediated rejection in lung transplantation.

21 itical to improving long-term survival after lung transplantation.

22 recent changes and advancements in heart and lung transplantation.

23 for clinical trials on immunosuppressants in lung transplantation.

24 tion to prevent and/or treat ACR in clinical lung transplantation.

25 ntaneously breathing patients as a bridge to lung transplantation.

26 ed their impact on outcomes before and after lung transplantation.

27 n, have somewhat arbitrarily been applied to lung transplantation.

28 rent recommendations regarding pregnancy and lung transplantation.

29 these diagnostic pillars are less robust in lung transplantation.

30 ear whether a VEGF blockade is beneficial in lung transplantation.

31 the use of extended-criteria donor organs in lung transplantation.

32 methods to measure obesity in candidates for lung transplantation.

33 practice and future directions of heart and lung transplantation.

34 advantageous for bridging to recovery or to lung transplantation.

35 l to 30 kg/m(2) may no longer contraindicate lung transplantation.

36 and plasma leptin levels with survival after lung transplantation.

37 njury focusing on kidney, liver, cardiac and lung transplantation.

38 pal factor limiting long-term survival after lung transplantation.

39 associated with the development of PGD after lung transplantation.

40 se of late morbidity and mortality following lung transplantation.

41 e major factor limiting long-term success of lung transplantation.

42 cause of early morbidity and mortality after lung transplantation.

43 ot result in better long-term outcomes after lung transplantation.

44 sis were higher in patients with LVRS before lung transplantation.

45 butor to early morbidity and mortality after lung transplantation.

46 allograft dysfunction limits survival after lung transplantation.

47 eurologic complications within 2 weeks after lung transplantation.

48 ly impairs graft function and survival after lung transplantation.

49 ty and compromised functional capacity after lung transplantation.

50 olar lavages obtained from 116 patients post lung transplantation.

51 y, may influence the clinical outcomes after lung transplantation.

52 r problem hampering long-term survival after lung transplantation.

53 cognitive dysfunction (POCD) is common after lung transplantation.

54 athogenesis of chronic rejection after human lung transplantation.

55 f 1.9 years, 11 patients died and 3 received lung transplantation.

56 c effects, and complications associated with lung transplantation.

57 llected and graded during surveillance after lung transplantation.

58 ed age, he is not considered a candidate for lung transplantation.

59 future development in the field of clinical lung transplantation.

60 ncreases in the risk of CLAD and death after lung transplantation.

61 AT1R and ETAR antibodies on graft outcome in lung transplantation.

62 ory failure provided they are candidates for lung transplantation.

63 and clinical effects of CMVIG after heart or lung transplantation.

64 r rate of respiratory failure while awaiting lung transplantation.

65 mize lung preservation leading to successful lung transplantation.

66 O) is being increasingly used as a bridge to lung transplantation.

67 LAD) is a major cause of allograft loss post-lung transplantation.

68 approach leading to long-term success after lung transplantation.

69 olar lavages obtained from 112 patients post-lung transplantation.

70 rimary outcome was the composite of death or lung transplantation.

71 The primary outcome was death or lung transplantation.

72 a median of 86 days (range, 44-185 d) after lung transplantation.

73 seudomonas associated allograft injury after lung transplantation.

74 major limitation of long-term survival after lung transplantation.

75 d the risk of both CLAD and graft loss after lung transplantation.

76 vative strategy of organ preservation before lung transplantation.

77 ms involved in the development of CLAD after lung transplantation.

78 y to prevent primary graft dysfunction after lung transplantation.

79 model reproducing the procedural sequence of lung transplantation.

80 B-related disease with a particular focus on lung transplantation.

81 ejection is a major cause of morbidity after lung transplantation.

82 rognosis in patients that do not qualify for lung transplantation.

83 6516 kidney, 2606 liver, 929 heart, and 705 lung transplantations.

84 nts were included (26 patients had undergone lung transplantation, 13 liver, 6 kidney, and 2 heart tr

85 nced lung disease who subsequently underwent lung transplantation (2004-2012).

86 (ISHLT [International Society for Heart and Lung Transplantation] 2013 grades), immunostaining, and

87 Of the 10,225 patients who underwent lung transplantation, 3127 (30.6%) had allografts expose

88 , 2.21; 95% CI, 1.53-3.17, P<0.001; HR after lung transplantation, 5.83; 95% CI, 3.12-10.9, P<0.001.

89 n 1 s was worse in patients with LVRS before lung transplantation (56.7% vs. 78.8%; P<0.05).

90 The patient had undergone left lung transplantation 8 years prior for pulmonary fibrosi

91 tal of 14 of 15 patients who did not undergo lung transplantation (93.3%) died after 40.3 +/- 27.8 da

92 As the experience with lung transplantation accrues, it has become increasingly

93 D+/R- heart transplant patients, whereas in lung transplantation, addition of CMVIG in recipients of

94 were independently associated with death or lung transplantation, adjusted for age, sex, and type of

95 hnique have contributed to improved outcomes.Lung transplantation advancements include the increasing

96 els were studied: hilar clamp and orthotopic lung transplantation after prolonged cold ischemia (OLT-

97 g transplantation vs. 66.2% in patients with lung transplantation alone).

98 surgery and Psychiatry, Journal of Heart and Lung Transplantation, American Journal of Transplantatio

99 .75; p=0.0011) for the composite of death or lung transplantation and 1.27 (1.00-1.60; p=0.046) for a

100 n=7) from patients with PAH undergoing heart/lung transplantation and compared with tissue obtained f

101 LA antibodies should be avoided in heart and lung transplantation and considered a risk factor for li

102 Both heart-lung transplantation and double-lung transplantation are

103 On multivariable analysis, heart-lung transplantation and double-lung transplantation wer

104 monly isolated gram-negative bacterium after lung transplantation and has been shown to up-regulate g

105 ntly worse comorbidities; nevertheless, both lung transplantation and heart-lung transplantation cand

106 Lung transplantation and heart-lung transplantation repr

107 t stature is associated with a lower rate of lung transplantation and higher rates of death and respi

108 rus (CARV) infections occur frequently after lung transplantation and may adversely impact outcomes.

109 These Abs can also develop de novo after lung transplantation and mediate allograft rejection.

110 g RV tissue of PAH patients undergoing heart/lung transplantation and nonfailing donors.

111 ograft fibrogenesis in the context of single-lung transplantation and represents a major step forward

112 ain cause of primary graft dysfunction after lung transplantation and results in increased morbidity

113 min concentration at the time of listing for lung transplantation and the rate of death after lung tr

114 p of the International Society for Heart and Lung Transplantation and The Transplantation Society.

115 d in lung tissues of IPF subjects undergoing lung transplantation, and CCN1 protein was predominantly

116 limiting factor for long-term survival after lung transplantation, and has previously been associated

117 America, International Society for Heart and Lung Transplantation, and Interagency Registry of Mechan

118 endations related to single versus bilateral lung transplantation, and review postlung transplantatio

119 America, International Society for Heart and Lung Transplantation, and the Interagency Registry of Me

120 continues to be a vexing problem in clinical lung transplantation, and the role played by passenger l

121 Early major neurologic complications after lung transplantation are common and carry substantial mo

122 Both heart-lung transplantation and double-lung transplantation are predictive of survival in trans

123 al follow up and vaccination responses after lung transplantation are scarce.

124 edicine, International Society for Heart and Lung Transplantation, Association of Organ Procurement O

125 were independently associated with death or lung transplantation at first follow-up RHC after initia

126 fty-seven consecutive patients who underwent lung transplantation at the Medical University of Vienna

127 probability of early clinical events (death, lung transplantation, atrial septostomy, PAH hospitaliza

128 ity and underweight are contraindications to lung transplantation based on their associations with mo

129 ctor (vWF) was significantly increased after lung transplantation because lung endothelial cells stro

130 LTRs) may be at greater risk of IA following lung transplantation because of the presence of Aspergil

131 hort study including all patients listed for lung transplantation between January 2008 and August 201

132 Bilateral lung transplantation (BLTx) is an established treatment

133 appropriately selected patients, LVRS before lung transplantation can impart substantial morbidity an

134 theless, both lung transplantation and heart-lung transplantation candidates in this era enjoyed lowe

135 Bacterial infections after lung transplantation cause airway epithelial injury and

136 The primary outcome was the time until lung transplantation censored at 1 year.

137 In lung transplantation, CMVIG should again only be used wi

138 A retrospective analysis of our lung transplantation cohort was performed (n=380).

139 ic disease experience similar survival after lung transplantation compared to those with other end-st

140 the null/null infants had died or undergone lung transplantation compared with 62% of the null/other

141 Lung transplantation confers large HRQL benefits, which

142 of cystic fibrosis (CF) patients undergoing lung transplantation continues to grow, as does the prev

143 ng to the International Society of Heart and Lung Transplantation criteria.

144 sing the International Society for Heart and Lung Transplantation criteria.

145 tory tests at 5, 11, 14, and 22 months after lung transplantation demonstrated sustained normalizatio

146 t requirements for tolerance induction after lung transplantation differ from other organs.

147 In lung transplantation, diverse clinical events may impact

148 study included adult patients who underwent lung transplantation during 2005-2008.

149 Immunosuppression therapy after lung transplantation fails to prevent bronchiolitis obli

150 Immunosuppression therapy following lung transplantation fails to prevent bronchiolitis obli

151 d to our institution and underwent bilateral lung transplantation for cystic fibrosis.

152 Of 177 patients who underwent lung transplantation for end-stage emphysema between 200

153 Lung transplantation for infants and children is an acce

154 ut ECMO (BLTx ventilation) or combined heart-lung transplantation for severe PH.

155 -type natriuretic peptide, hemodynamics) and lung-transplantation-free survival.

156 eight were finally found to be suitable for lung transplantation from an ECMO bridge.

157 was queried for adult patients who underwent lung transplantation from May 1, 2005, through December

158 base, all adult patients undergoing isolated lung transplantation from May 2005 through September 201

159 R (pAMR) International Society for Heart and Lung Transplantation grade (P<0.001) and association wit

160 fined as International Society for Heart and Lung Transplantation grade 2R or higher cellular rejecti

161 tion (>/= International Society of Heart and Lung Transplantation grade 2R); however, the frequency o

162 come was International Society for Heart and Lung Transplantation grade 3 PGD at 48 or 72 hours post-

163 tion and International Society for Heart and Lung Transplantation grade and the performance metrics o

164 but given the dearth of donor lungs, single lung transplantation has become commonplace for most SSc

165 Central airway stenosis (CAS) after lung transplantation has been attributed in part to chro

166 Pregnancy after lung transplantation has been described, but pregnancy a

167 Lung transplantation has helped to extend the lives of p

168 eases, but the exact role of eosinophilia in lung transplantation has not been thoroughly investigate

169 Outcomes of single- and double-lung transplantation have not been rigorously assessed s

170 atients with chronic lung disease undergoing lung transplantation have pre-existing Abs against lung-

171 Patients with SSc undergoing lung transplantation have similar rates of chronic rejec

172 lation (MV) can be used as a bridge to heart-lung transplantation (HLT).

173 of patients undergoing either lung or heart-lung transplantation in a tertiary transplantation cente

174 LVRS remains a viable option as a bridge to lung transplantation in appropriately selected patients,

175 iated with better graft survival than single-lung transplantation in patients with IPF.

176 Lung transplantation in patients with SSc remains contro

177 dications and patient selection criteria for lung transplantation in patients with SSc, discuss the i

178 l outcomes for patients after combined heart-lung transplantation in the current era.

179 Despite its complexity, lung transplantation in the cystic fibrosis population i

180 s not associated with 1-year mortality after lung transplantation in the LAS era, perhaps because of

181 year mortality in 9,073 adults who underwent lung transplantation in the United States between May 20

182 ctive pulmonary disease (COPD) who underwent lung transplantation in the United States between May 4,

183 Patients with CF who underwent lung or heart-lung transplantation in the United States or United King

184 ansplant-free survival (ie, time to death or lung transplantation) in the Dallas cohort.

185 After lung transplantation, increased left ventricular (LV) fi

186 osite end point of death, atrial septostomy, lung transplantation, initiation of treatment with intra

187 43 in kidney, 17 in heart, 12 in liver, 1 in lung transplantation) investigated 95 correlates and 24

188 Obliterative bronchiolitis (OB) post-lung transplantation involves IL-17-regulated autoimmuni

189 Heart lung transplantation is a viable treatment option for pa

190 Lung transplantation is a worthwhile treatment option to

191 The survival rate following lung transplantation is among the lowest of all solid-or

192 Lung transplantation is an effective treatment for patie

193 ent of donor-specific antibodies (DSA) after lung transplantation is associated with antibody mediate

194 ischemia (>/=6 hours) on outcomes following lung transplantation is controversial.

195 issues and organs, tolerance induction after lung transplantation is critically dependent on central

196 timulation blockade-mediated tolerance after lung transplantation is dependent on programmed cell dea

197 evidence for mTOR inhibitor use in heart and lung transplantation is examined in this review.

198 Lung transplantation is limited by a scarcity of suitabl

199 nhibitors in de novo immunosuppression after lung transplantation is not well defined.

200 respiratory failure within 2-4 years unless lung transplantation is performed.

201 The barrier to long-term success after lung transplantation is the development of chronic lung

202 Heart-lung transplantation or bilateral lung transplantation is the final pathway for a minority

203 Lung transplantation is the only viable option for patie

204 (HA) fragments, in clinical or experimental lung transplantation is uncertain.

205 ct of HCV infection on survival in heart and lung transplantation is unclear.

206 transplantation and the rate of death after lung transplantation is unknown.

207 h is one of the most common infections after lung transplantation, is associated with chronic lung al

208 syndrome (BOS), the major cause of death on lung transplantation, is characterized by bronchiolar in

209 fined as International Society for Heart and Lung Transplantation (ISHLT) grade 2R or higher at endom

210 The International Society of Heart and Lung Transplantation (ISHLT) has initiated a multidiscip

211 using the International Society for Heart & Lung Transplantation (ISHLT)-defined criteria.

212 When selecting a donor for lung transplantation, it is generally believed that the

213 immunosuppression, long-term survival after lung transplantation lags behind that for other solid or

214 ibed, but pregnancy after living donor lobar lung transplantation (LDLT) has not been reported.

215 Forty-eight hours after lung transplantation, left lungs were collected and wet-

216 Performing lobar lung transplantation (LLT) can circumvent issues with do

217 one, or were on the waiting list to undergo, lung transplantation, lobectomy, or lung volume-reductio

218 In lung transplantation, long-term management remains limit

219 act the time to development of BOS or RAS in lung transplantation (low vs high LVD: 38.5 vs 86.0 mont

220 on (ACR) is a major early complication after lung transplantation (LT) and is a risk factor for chron

221 hepatitis B (HBV) vaccination strategies for lung transplantation (LT) candidates are not well establ

222 ease (SSc-LD) is often a contraindication to lung transplantation (LT) due to concerns that extrapulm

223 The survival benefit of lung transplantation (LT) in adult patients with cystic

224 Lung transplantation (LT) is an established treatment fo

225 imus twice-daily (TAC BID) is widely used in lung transplantation (LT), but there are little data on

226 imus twice-daily (TAC BID) is widely used in lung transplantation (LT), but there are little data on

227 After lung transplantation (LT), early prediction of grade 3 p

228 After lung transplantation (LT), immunoglobulin (Ig) G plasma

229 Sarcoidosis is reported to recur after lung transplantation (LT).

230 older) and younger (age 18-64) adults after lung transplantation (LT).

231 essive lung destruction ultimately requiring lung transplantation (LT).

232 disorders (SRBD) are common in patients with lung transplantation (LT); however, there are few data a

233 case series to date of hyperammonemia after lung transplantation (LTx) and discuss a treatment proto

234 Is) among consecutive patients who underwent lung transplantation (LTx) at a single center from 2006

235 Successful lung transplantation (LTx) depends on multiple component

236 ctor affecting morbidity and mortality after lung transplantation (LTX) is bronchiolitis obliterans s

237 Lung transplantation (LTx) is offered to older and more

238 prevalence of the CF phenotype with NP after lung transplantation (LTx) is unknown.

239 etting, although long-term outcome after DCD lung transplantation (LTx) remains largely unknown.

240 ronchiolitis obliterans syndrome (BOS) after lung transplantation (LTx) results from bronchial epithe

241 nt cause of early morbidity and mortality in lung transplantation (LTX) with an incidence of 8% to 20

242 t of patients with various diseases awaiting lung transplantation (LTx).

243 olitis (LB), and respiratory infection after lung transplantation (LTx).

244 rome (BOS) remain major limiting factors for lung transplantation (LTx).

245 portion of sensitized candidates waiting for lung transplantation (LTx).

246 corporeal life support (ECLS) as a bridge to lung transplantation (LuTx) is a promising option for pa

247 severe BO patients should be considered for lung transplantation (LuTX).

248 Early epithelial injury after lung transplantation may contribute to development of br

249 Acute rejection, a common complication of lung transplantation, may promote obliterative bronchiol

250 dicate that lymphatic vessel formation after lung transplantation mediates HA drainage and suggest th

251 For this purpose, we employed an orthotopic lung transplantation model in mice.

252 A rodent heterotopic working heart-lung transplantation model was used for studying acute a

253 using either porcine venous tissue or a pig lung transplantation model, which recapitulates pulmonar

254 subjects with nondiseased lungs donated for lung transplantation (n = 11) and those with chronic obs

255 pulmonary disease (COPD) who were undergoing lung transplantation (n = 16) was evaluated for CCR2 wit

256 Prognosis remains very poor, and currently lung transplantation offers the only hope of survival.

257 estigated the outcome of patients bridged to lung transplantation on ECLS technologies, mainly extrac

258 Heart-lung transplantation or bilateral lung transplantation i

259 ted hospitalization, death, or lung surgery (lung transplantation or pulmonary endarterectomy) during

260 ression of disease to warrant evaluation for lung transplantation (or retransplantation).

261 erwent single-lung and 2124 underwent double-lung transplantation) or COPD (n = 3174, of whom 1299 un

262 ill associated with higher rates of death or lung transplantation (P<0.01).

263 as also present in bronchoalveolar lavage of lung transplantation patients.

264 CMV-seropositive lung transplantation recipients were included in the dis

265 Lobar lung transplantation recipients were older (54 +/- 10 vs

266 jectors; International Society for Heart and Lung Transplantation rejection grade >/= 2R) and patient

267 omplications and their impact on outcomes in lung transplantation remain largely unknown.

268 Long-term survival after lung transplantation remains poor, yet modifiable risk f

269 Early major neurologic complications after lung transplantation represent a major source of morbidi

270 Lung transplantation and heart-lung transplantation represent surgical options for trea

271 Lung transplantation represents a viable therapeutic opt

272 ntation) were identified as having undergone lung transplantation since May 2005.

273 After lung transplantation, spirometric values are routinely f

274 vious studies in a mouse model of orthotopic lung transplantation suggested a requirement for IL-17.

275 key role in constrictive bronchiolitis after lung transplantation, the typical hallmark of chronic re

276 ts with worsening pulmonary disease awaiting lung transplantation, those supported via ECMO with spon

277 Subjects who underwent lung transplantation underwent endobronchial tissue oxim

278 review our experience using LLT and standard lung transplantation using a pediatric donor (PDLT) for

279 pact of using older donors on outcomes after lung transplantation using current protocols.

280 ifferent (59.7% in patients with LVRS before lung transplantation vs. 66.2% in patients with lung tra

281 The unadjusted rate of lung transplantation was 94.5 per 100 person-years among

282 al need-based lung allocation system, double-lung transplantation was associated with better graft su

283 ssociated with poorer OS (P < 0.05), whereas lung transplantation was associated with no difference i

284 lume reduction surgery (LVRS) as a bridge to lung transplantation was first advocated in 1995 and pub

285 Lung transplantation was performed 22.9+/-15.9 months af

286 Unilateral left lung transplantation was performed in mice across varyin

287 m a prospective study of mental health after lung transplantation, we identified 1-year survivors and

288 T cells on bronchiolitis obliterans (BO) in lung transplantation, we used an established tracheal tr

289 lysis, heart-lung transplantation and double-lung transplantation were associated with improved survi

290 nor specific anti-HLA antibodies (DSA) after lung transplantation were preemptively treated with ther

291 pulmonary veno-occlusive disease undergoing lung transplantation were significantly lower than those

292 nuary 2002 and January 2005, 209 consecutive lung transplantations were performed with LPD.

293 erwent single-lung and 1875 underwent double-lung transplantation) were identified as having undergon

294 n edema is a common early complication after lung transplantation where the hypoxia-induced vascular

295 tcomes of patients who underwent LVRS before lung transplantation with a matched cohort of patients w

296 iferative disorder (PTLD), a complication of lung transplantation with an incidence ranging from as m

297 study, we report our experience with PTLD in lung transplantation with CMV Ig prophylaxis.

298 ons with very severe COPD (n = 4) treated by lung transplantation with unused donor lungs (n = 4) ser

299 he main reason for poor long-term outcome of lung transplantation, with bronchiolitis obliterans (BO)

300 incidence of graft rejection after liver and lung transplantation, with significantly higher rates of

301 dnDSA are common after lung transplantation, with the majority being DQ DSA.